Cargando…

Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender

PURPOSE OF REVIEW: Over the last decades, several classes of drugs have been introduced for the treatment of patients with heart failure with reduced ejection fraction (HFrEF). Their use has been supported by randomized controlled trials that have demonstrated improved patient outcomes. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iacoviello, Massimo, Pugliese, Rosanna, Correale, Michele, Brunetti, Natale Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Clinical Heart Failure (T.E. Meyer, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653313/ https://www.ncbi.nlm.nih.gov/pubmed/36197626 http://dx.doi.org/10.1007/s11897-022-00583-w

Ejemplares similares

Missed Opportunities in the Diagnosis of Heart Failure: Evaluation of Pathways to Determine Sources of Delay to Specialist Evaluation
por: Kwok, Chun Shing, et al.
Publicado: (2022)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Margonato, Davide, et al.
Publicado: (2020)

Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic
por: Gagnon, Luke R., et al.
Publicado: (2022)

Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis
por: Putri, Desak Ketut Sekar Cempaka, et al.
Publicado: (2023)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Epidemiology of Asymptomatic Pre-heart Failure: a Systematic Review
por: Bergamasco, Aurore, et al.
Publicado: (2022)

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
por: Guazzi, Marco, et al.
Publicado: (2021)

The Emerging Role of Cardiac Conduction System Pacing as a Treatment for Heart Failure
por: Ali, Nadine, et al.
Publicado: (2020)

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure
por: Gijsberts, Crystel M, et al.
Publicado: (2016)

Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia
por: Abohammar, Samah, et al.
Publicado: (2017)

Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Beale, Anna L, et al.
Publicado: (2019)

Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction
por: Salah, Khibar, et al.
Publicado: (2019)

Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction
por: Son, Mi Kyoung, et al.
Publicado: (2020)

Diastolic index as a short-term prognostic factor in heart failure with preserved ejection fraction
por: Hoshida, Shiro, et al.
Publicado: (2020)

Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review
por: Zheng, Sean L, et al.
Publicado: (2016)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Implantation of a vagus nerve stimulator for patients with heart failure with reduced ejection fraction: An educational video
por: Al Rameni, Dina, et al.
Publicado: (2022)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015)

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Zheng, Sean Lee, et al.
Publicado: (2018)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

Heart Failure with Preserved Ejection Fraction—a Concise Review
por: Adamczak, Daria M., et al.
Publicado: (2020)

Non-invasive intraventricular pressure differences estimated with cardiac MRI in subjects without heart failure and with heart failure with reduced and preserved ejection fraction
por: Londono-Hoyos, Francisco, et al.
Publicado: (2019)

Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction
por: Alcidi, Gianmarco, et al.
Publicado: (2023)

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
por: Ganesananthan, Sashiananthan, et al.
Publicado: (2020)

Development of algorithms for determining heart failure with reduced and preserved ejection fraction using nationwide electronic healthcare records in the UK
por: Sundaram, Varun, et al.
Publicado: (2022)

Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model
por: Sotomi, Yohei, et al.
Publicado: (2023)

Obesity paradox in heart failure patients – Female gender characteristics-KAMC-single center experience
por: Khaled, Sheeren, et al.
Publicado: (2017)

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction
por: Mentz, Robert J, et al.
Publicado: (2015)

Developing a contemporary community clinic for patients with heart failure with preserved ejection fraction within the current National Health Service model
por: Tran, Patrick, et al.
Publicado: (2022)

Extracellular cardiac matrix biomarkers in patients with reduced ejection fraction heart failure as predictors of response to cardiac resynchronisation therapy: a systematic review
por: McAloon, Christopher J, et al.
Publicado: (2017)

Prognostic value of left ventricular mitral annular longitudinal displacement obtained by tissue Doppler imaging in patients with heart failure with reduced ejection fraction
por: Sengeløv, Morten, et al.
Publicado: (2021)

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England
por: Kolovos, Spyros, et al.
Publicado: (2023)

Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study
por: Abboud, Andrew, et al.
Publicado: (2021)

Colchicine in patients with heart failure and preserved left ventricular ejection fraction: rationale and design of a prospective, randomised, open-label, crossover clinical trial
por: Shchendrygina, Anastasia, et al.
Publicado: (2023)

Association of early versus delayed normalisation of left ventricular ejection fraction with mortality in ischemic cardiomyopathy
por: Schiffer, Walter B, et al.
Publicado: (2021)

Revascularization in ischemic heart failure with reduced left ventricular ejection fraction. The impact of complete revascularization
por: Pyka, Łukasz, et al.
Publicado: (2017)

Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials
por: Suebsaicharoen, Thanakit, et al.
Publicado: (2023)

Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35%
por: Wasfy, Jason H, et al.
Publicado: (2023)

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis
por: Basile, Christian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tb1l43877mm4q0sk5388er5bde